Abstract 1700
Background
Limited evidence is available regarding survival benefit of SLC in patients with ABGC. After failure of first-line treatment, currently no "standard" second-line therapy is available. There is a lack of randomized clinical trials and well-designed population-based study to address this important question in the management of ABGC. In this population-based cohort study we evaluated if SLC prolongs survival in patients with ABGC.
Methods
Patients with biopsy proven ABGC who were diagnosed in the province of Saskatchewan during the period of 2006 to 2015 and received first-line chemotherapy were assessed. Based on the use of SLC, patients were divided into ‘Treatment’ group or ‘Control’. Cox proportional multivariate analyses were performed to determine survival benefit of SLC.
Results
136 eligible patients with median age of 66 (IQR, 55-73) and M:F of 1:1.34 were identified. Primary tumor sites were as followed: gallbladder 31%, intrahepatic cholangiocarcinoma 36%, bile duct 23%, and ampullary 10%. 68% patients had metastatic disease.37% patients received SLC and of those 42% received combination therapy. There were significant differences between the two groups with respect to age and baseline liver function. The median overall survival (mOS) of treatment group was 17 months (95%CI, 12.5-21.5) vs. 7 months (5.3-8.7) of control (p < 0.0001). Patients who received combination SLC had mOS of 20 months (14.0-26.1) vs. 17 (13.5-20.5) with single agent chemotherapy (p = 0.73). On progression 36% received 3rd or subsequent line treatment. On univariate analysis SLC HR 0.51 (0.35-0.73), bilirubin 0.52 (0.34-0.79), and neutrophil to lymphocyte ratio (NLR) 1.11 (1.07-1.16) significantly correlated with survival. Test for interaction between SLC and all the other variables were not significant. On multivariate analysis SLC HR 0.55 (0.36-0.83) and NLR 1.10 (1.05-1.15) were significantly correlated with survival.
Conclusions
This well-designed population based cohort study suggests a substantial survival benefit associated with SLC. Patients with ABGC who are potential candidate for chemotherapy should be offered active treatment or participation in the clinical trial.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Saskatchewan Cancer Agency Research Grant.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5063 - Does Nutritional Status Affect Treatment Tolarability, Response and Survival in Metastatic Gastric Cancer Patients? Results of Prospective Multicenter Study
Presenter: Senem Karabulut
Session: Poster Display session 2
Resources:
Abstract
2717 - Ramucirumab use in patients with Advanced Gastric Cancer (AGC) or gastro-oesophageal junction (GEJ) adenocarcinoma in Spain: RAMIS observational study
Presenter: Federico Longo Munoz
Session: Poster Display session 2
Resources:
Abstract
3187 - Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor: Exploratory analysis in the patients who were enrolled in JCOG0705/KGCA01 phase III trial (REGATTA) and could continue chemotherapy
Presenter: Takaki Yoshikawa
Session: Poster Display session 2
Resources:
Abstract
4765 - A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab based therapy
Presenter: Qian Li
Session: Poster Display session 2
Resources:
Abstract
3500 - Randomised phase 2 trial of first-line docetaxel, carboplatin, capecitabine (CTX) and epirubicin, oxaliplatin, capecitabine (EOX) in advanced esophagogastric adenocarcinoma (SEED)
Presenter: Peter Petersen
Session: Poster Display session 2
Resources:
Abstract
5197 - Ramucirumab in the treatment of refractory metastatic gastric cancer: results from the RamSelGa trial.
Presenter: Alexey Tryakin
Session: Poster Display session 2
Resources:
Abstract
2011 - Regorafenib in combination with Paclitaxel for beyond first-line treatment of advanced esophagogastric cancer (REPEAT): a phase Ib trial with expansion cohort
Presenter: Mohammed Khurshed
Session: Poster Display session 2
Resources:
Abstract
2117 - The relationship between the survival and fixed dosing of S-1 in advanced gastric cancer patients by pooled analysis using individual data from four Japanese randomized phase III trials
Presenter: Wataru Ichikawa
Session: Poster Display session 2
Resources:
Abstract
2669 - A Phase 1b Study of Oraxol in Combination with Ramucirumab in Patients with Gastric or Esophageal Cancers who failed previous chemotherapy
Presenter: Ming Huang Chen
Session: Poster Display session 2
Resources:
Abstract
3240 - Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in European patients with heavily pretreated metastatic gastric cancer (mGC): an analysis of the TAGS study
Presenter: Maria Alsina
Session: Poster Display session 2
Resources:
Abstract